Positron Emission Tomography (PET) was much more sensitive and more accurate than conventional imaging methods in detecting response to treatment in sarcoma patients, according to a UCLA study that is among the first to directly compare PET to CT scanning.

Positron emission tomography (PET) is a useful diagnostic tool that supports the need for more accurate staging of lung cancer and improved treatment for patients, concludes an extensive systematic review published online today in Journal of National Cancer Institute.

Positron emission tomography or PET scans can help clinicians diagnose and treat some cancers, but it is not clear yet whether the imaging technology helps people with cancer live longer and healthier lives, according to a comprehensive review by the U.K. National Health Service.

With positron emission tomography (PET) imaging, seeing is believing: Evaluating a patient’s response to chemotherapy for non-Hodgkin lymphoma (NHL) typically involves visual interpretation of scans of cancer tumors.

Combined positron emission tomography and computed tomography (PET/CT) is currently widely used in the clinical diagnosis of cancer to provide functional and morphological imaging. The value of PET/CT in detection of the recurrence and metastasis of colorectal cancer (CRC) was recently confirmed in an article appearing in the October 7 issue of the World Journal of Gastroenterology.

Researchers in Australia have shown that positron emission tomography (PET) that uses a radioactive sugar molecule is more useful than mammography and ultrasound in predicting a breast tumour’s response to chemotherapy and, therefore, the patient’s ultimate likelihood of survival.

Current PET-CT scanners with standard commercial software designed to provide images of the heart are falsely indicating coronary artery disease in as many as 40 percent of patients, according to a study published on the cover page of the Journal of Nuclear Medicine (03 July).

Removing infected vascular grafts in patients involves a complex surgical procedure with high risks. Molecular imaging with positron emission tomography (PET)/computed tomography (CT) effectively diagnoses and differentiates infection, noted Israeli researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

Moving from computer simulation to patient images, researchers are now demonstrating the benefits that time-of-flight (TOF)/PET (positron emission tomography) imaging can provide for cancer patients. The result? Superior images and shorter patient scan times for starters, according to a study released at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals, June 2-6 in Washington, D.C.

Early metabolic imaging with positron emission tomography (PET) accurately identifies patients responding to chemotherapy for esophageal cancer, noted German researchers at the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals.

An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients-provided by positron emission tomography (PET) imaging-can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.